Strattera for Sensory Reactivity, Emotional Lability, and Anxiety
Strattera (atomoxetine) will help with emotional lability and anxiety in ADHD patients, but there is no evidence it targets sensory reactivity specifically.
Evidence for Emotional Lability
Atomoxetine demonstrates robust efficacy for emotional dysregulation in ADHD patients. In adults with ADHD, 32% exhibited emotional dysregulation (temper, affective lability, emotional overreactivity) at baseline, and these symptoms showed treatment response to atomoxetine that was at least as large as core ADHD symptoms 1. A separate integrated analysis of 2,846 adult ADHD patients found atomoxetine produced significant improvements in emotional control with an effect size of 0.32 in patients with baseline impairment 2.
The mechanism appears direct rather than secondary to ADHD improvement, as emotional control improvements correlated with but were independent of core symptom reduction 2.
Evidence for Anxiety
The FDA label explicitly states that atomoxetine does not worsen anxiety in ADHD patients with comorbid anxiety disorders 3. Two pivotal trials support this:
Pediatric trial (ages 8-17, n=176): Atomoxetine at 1.2 mg/kg/day did not worsen anxiety as measured by the Pediatric Anxiety Rating Scale in patients with ADHD plus separation anxiety disorder, generalized anxiety disorder, or social phobia 3
Adult trial (ages 18-65, n=442): Atomoxetine up to 100 mg/day significantly improved both ADHD symptoms and social anxiety (LSAS Total score change: -22.9 vs -14.4 for placebo, P<.001) 4
A systematic review confirmed atomoxetine reduced rather than exacerbated anxiety symptoms in children and adolescents with comorbid ADHD and anxiety 5. Direct comparison studies show atomoxetine produces significantly greater anxiety reduction than methylphenidate starting at week 4 of treatment 6.
Sensory Reactivity
No evidence exists in the provided literature that atomoxetine targets sensory reactivity. This symptom domain was not measured in any of the clinical trials. Sensory processing issues, while common in ADHD, are not an FDA-approved indication for atomoxetine.
Clinical Implementation
For emotional lability and anxiety:
- Start atomoxetine at 0.8 mg/kg/day in children, titrate to 1.2 mg/kg/day 3
- In adults, start at 40 mg/day, titrate to 80-100 mg/day 4
- Expect anxiety benefits by week 4, with continued improvement through week 12-16 6, 4
- Effect sizes for nonstimulants (0.7) are lower than stimulants (1.0) for core ADHD symptoms, but atomoxetine may be preferable when anxiety is prominent 7
Important Caveats
The FDA label notes postmarketing reports of anxiety as an adverse effect 3, creating an apparent contradiction with trial data. This likely reflects individual variability—most patients improve, but monitor closely for paradoxical worsening, particularly in the first 2-4 weeks.
High discontinuation rates (36% in adults, 16% in children) occurred even in controlled trials 3, often due to tolerability issues (insomnia, nausea, dry mouth) rather than lack of efficacy 4.
For sensory reactivity specifically, consider alternative interventions as atomoxetine lacks supporting evidence for this domain.